A 1981 Cannabinoid Review Distinguished Animal Potency From Brain Drug Concentration
A 1981 review of anticonvulsant cannabinoid research described large species differences in CBD potency and distinguished administered dose from brain concentration. Its preclinical synthesis should not be treated as a current treatment recommendation.
The source compared several seizure models
The review discussed CBD, THC and prototype anticonvulsants across animal experiments. It described CBD as relatively selective compared with THC in the balance of depressant and excitatory effects, while noting substantial variation in CBD potency between species. Those claims summarize the historical evidence reviewed, rather than a new clinical trial.
Dose differences need not mean target differences
The abstract attributed some large administered-dose potency differences to drug disposition because brain concentrations were similar. That comparison illustrates why dose alone can mislead when species absorb, distribute or metabolize compounds differently. It does not establish that equal brain concentrations guarantee equal efficacy or safety.
Repeated-exposure outcomes were mixed
The review reported tolerance in one CBD seizure model and increased sensitivity in two others. This limits a blanket claim that CBD either always or never becomes tolerant. Model-specific electrical or behavioral outcomes cannot substitute for sustained seizure control in patients.
Applying the distinction
For a cross-species comparison, keep the administered amount, measured brain exposure and seizure endpoint in separate columns. A large dose difference can coexist with a smaller exposure difference. Conversely, matching one concentration does not remove differences in the experimental seizure challenge or establish that a clinical dose will have the same benefit.
What the finding means
The source is useful for understanding species, exposure and endpoint differences in early cannabinoid research. Its historical epilepsy terminology and therapeutic proposals are not presented as current clinical guidance. The study type and actual measurement must remain attached to the conclusion.
For related interpretation, see interpreting cannabis tolerance claims.
Research reference
Karler R; Turkanis SA (1981). The cannabinoids as potential antiepileptics. Journal of clinical pharmacology. doi:10.1002/j.1552-4604.1981.tb02624.x.
This discussion draws on the supplied review abstract.
